Advertisement

Current Diabetes Reports

, 18:6 | Cite as

Type 2 Diabetes and Thiazide Diuretics

  • André J. ScheenEmail author
Other Forms of Diabetes and Its Complications (JJ Nolan and H Thabit, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Other Forms of Diabetes and Its Complications

Abstract

Purpose of Review

In patients with prediabetes or type 2 diabetes, the use of thiazides as antihypertensive agents has been challenged because associated metabolic adverse events, including new-onset diabetes.

Recent Findings

These metabolic disturbances are less marked with low-dose thiazides and, in most but not all studies, with thiazide-like diuretics (chlorthalidone, indapamide) than with thiazide-type diuretics (hydrochlorothiazide). In post hoc analyses of subgroups of patients with hypertension and type 2 diabetes, thiazides resulted in a significant reduction in cardiovascular events, all-cause mortality, and hospitalization for heart failure compared to placebo and generally were shown to be non-inferior to other antihypertensive agents.

Summary

Benefits attributed to thiazide diuretics in terms of cardiovascular event reduction outweigh the risk of worsening glucose control in type 2 diabetes and of new-onset diabetes in non-diabetic patients. Thiazides still play a key role in the management of patients with type 2 diabetes and hypertension.

Keywords

Cardiovascular disease Diuretic Hypertension SGLT2 inhibitor Thiazide Type 2 diabetes 

Notes

Compliance with Ethical Standards

Conflict of Interest

No sources of funding were used to assist in the preparation of this manuscript. No conflicts of interest are directly relevant to the content of this manuscript.

A.J. Scheen has received lecturer/scientific advisor/clinical investigator fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, NovoNordisk, Sanofi, and Servier.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

References

Papers of particular interest, published recently, have been highlighted as: •Of importance •• Of major importance

  1. 1.
    Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther. 2014;19(1):5–13.  https://doi.org/10.1177/1074248413497257.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601–10.  https://doi.org/10.1016/S0140-6736(12)60987-8.PubMedCrossRefGoogle Scholar
  3. 3.
    McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2(10):843–51.  https://doi.org/10.1016/S2213-8587(14)70031-2.PubMedCrossRefGoogle Scholar
  4. 4.
    Bahtiyar G, Gutterman D, Lebovitz H. Heart failure: a major cardiovascular complication of diabetes mellitus. Curr Diabetes Rep. 2016;16(11):116.  https://doi.org/10.1007/s11892-016-0809-4.CrossRefGoogle Scholar
  5. 5.
    Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006.  https://doi.org/10.1161/CIRCRESAHA.116.305697.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Grossman E, Verdecchia P, Shamiss A, Angeli F, Reboldi G. Diuretic treatment of hypertension. Diabetes Care. 2011;34(Suppl 2):S313–9.  https://doi.org/10.2337/dc11-s246.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13(9):639–43.  https://doi.org/10.1111/j.1751-7176.2011.00512.x.CrossRefGoogle Scholar
  8. 8.
    Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother. 2014;15(4):527–47.  https://doi.org/10.1517/14656566.2014.879118.PubMedCrossRefGoogle Scholar
  9. 9.
    Rosendorff C. Why are we still using hydrochlorothiazide? J Clin Hypertens (Greenwich). 2011;13(12):867–9.  https://doi.org/10.1111/j.1751-7176.2011.00566.x.CrossRefGoogle Scholar
  10. 10.
    DiNicolantonio JJ, Bhutani J, Lavie CJ, O’Keefe JH. Evidence-based diuretics: focus on chlorthalidone and indapamide. Futur Cardiol. 2015;11(2):203–17.  https://doi.org/10.2217/fca.14.83.CrossRefGoogle Scholar
  11. 11.
    Robinson DM, Wellington K. Indapamide sustained release: a review of its use in the treatment of hypertension. Drugs. 2006;66(2):257–71.  https://doi.org/10.2165/00003495-200666020-00011.PubMedCrossRefGoogle Scholar
  12. 12.
    Salvetti A, Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol. 2006;17(4 Suppl 2):S25–9.  https://doi.org/10.1681/ASN.2005121329.PubMedCrossRefGoogle Scholar
  13. 13.
    Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(12):1401–9.  https://doi.org/10.1001/archinte.165.12.1401.PubMedCrossRefGoogle Scholar
  14. 14.
    Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich). 2004;6(9):532–40.CrossRefGoogle Scholar
  15. 15.
    Cooper-DeHoff RM. Thiazide-induced dysglycemia: it’s time to take notice. Expert Rev Cardiovasc Ther. 2008;6(10):1291–4.  https://doi.org/10.1586/14779072.6.10.1291.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-induced hyperglycaemia and diabetes. Drug Saf. 2015;38(12):1153–68.  https://doi.org/10.1007/s40264-015-0339-z.PubMedCrossRefGoogle Scholar
  17. 17.
    Warram JH, Laffel LM, Valsania P, Christlieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med. 1991;151(7):1350–6.  https://doi.org/10.1001/archinte.1991.00400070114014.PubMedCrossRefGoogle Scholar
  18. 18.
    • Lin JJ, Chang HC, Ku CT, Chen HY. Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. Eur Rev Med Pharmacol Sci. 2016;20(13):2926–46. This meta-analysis concludes that while thiazide diuretics are still a recommended medication of hypertension therapy for type 2 diabetes, treatment with low-dose HCTZ should be attempted to evaluate the effectiveness and adverse metabolic effects. PubMedGoogle Scholar
  19. 19.
    •• Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10—should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35(5):922–44.  https://doi.org/10.1097/HJH.0000000000001276. This systematic review compares the effects on cardiovascular and renal outcomes of blood pressure lowering by different drug classes in patients with and without diabetes mellitus. PubMedCrossRefGoogle Scholar
  20. 20.
    • Liang W, Ma H, Cao L, Yan W, Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med. 2017;21(11):2634–42.  https://doi.org/10.1111/jcmm.13205. This comparative meta-analysis concludes that using thiazide-like diuretics is superior to thiazide-type diuretics in reducing blood pressure without increasing the incidence of metabolic disturbances. PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    • Yang Y, Xu H. Comparing six antihypertensive medication classes for preventing new-onset diabetes mellitus among hypertensive patients: a network meta-analysis. J Cell Mol Med. 2017;21(9):1742–50.  https://doi.org/10.1111/jcmm.13096. This network meta-analysis concludes that hydrochlorothiazide exhibits a reliable performance in comparison with other antihypertensive agents although RAS blockers appear superior. PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    • Brunstrom M, Eliasson M, Nilsson PM, Carlberg B. Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews. J Hypertens. 2017;35(3):453–62.  https://doi.org/10.1097/HJH.0000000000001183. This paper concludes that the available evidence supports treatment in people with type 2 diabetes and systolic blood pressure more than 140 mmHg, using any of the major antihypertensive drug classes, includinf thiazide diuretics. PubMedCrossRefGoogle Scholar
  23. 23.
    • Zhang X, Zhao Q. Association of thiazide-type diuretics with glycemic changes in hypertensive patients: a systematic review and meta-analysis of randomized controlled clinical trials. J Clin Hypertens (Greenwich). 2016;18(4):342–51.  https://doi.org/10.1111/jch.12679. This meta-analysis concludes that thiazide-type diuretics are associated with significant but small adverse glycemic effects in hypertensive patients and that a lower dose might reduce or avoid glycemic changes. CrossRefGoogle Scholar
  24. 24.
    •• Remonti LR, Dias S, Leitao CB, Kramer CK, Klassman LP, Welton NJ, et al. Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes—network meta-analysis of randomized trials. J Diabetes Complicat. 2016;30(6):1192–200.  https://doi.org/10.1016/j.jdiacomp.2016.04.020. This network meta-analysis concludes that there is no benefit of a single antihypertensive class in reduction of mortality in hypertensive patients with type 2 diabetes. PubMedCrossRefGoogle Scholar
  25. 25.
    Mukete BN, Rosendorff C. Effects of low-dose thiazide diuretics on fasting plasma glucose and serum potassium-a meta-analysis. J Am Soc Hypertens. 2013;7(6):454–66.  https://doi.org/10.1016/j.jash.2013.05.004.PubMedCrossRefGoogle Scholar
  26. 26.
    Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, Shocken D, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983;32(2):106–11.  https://doi.org/10.2337/diab.32.2.106.PubMedCrossRefGoogle Scholar
  27. 27.
    Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48(2):219–24.  https://doi.org/10.1161/01.HYP.0000231552.10054.aa.PubMedCrossRefGoogle Scholar
  28. 28.
    Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4(2):136–47.  https://doi.org/10.1016/S2213-8587(15)00377-0.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041–6.  https://doi.org/10.1161/HYPERTENSIONAHA.114.05021.PubMedCrossRefGoogle Scholar
  30. 30.
    Weir MR, Flack JM, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Am J Med. 1996;101(3A):83S–92S.  https://doi.org/10.1016/S0002-9343(96)00271-9.PubMedCrossRefGoogle Scholar
  31. 31.
    Price AL, Lingvay I, Szczepaniak EW, Wiebel J, Victor RG, Szczepaniak LS. The metabolic cost of lowering blood pressure with hydrochlorothiazide. Diabetol Metab Syndr. 2013;5(1):35.  https://doi.org/10.1186/1758-5996-5-35.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Eriksson JW, Jansson PA, Carlberg B, Hagg A, Kurland L, Svensson MK, et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension. 2008;52(6):1030–7.  https://doi.org/10.1161/HYPERTENSIONAHA.108.119404.PubMedCrossRefGoogle Scholar
  33. 33.
    Muiesan ML, Salvetti M, Belotti E, Paini A, Rosei CA, Aggiusti C, et al. Effects of barnidipine in comparison with hydrochlorothiazide on endothelial function, as assessed by flow mediated vasodilatation in hypertensive patients. Blood Press. 2011;20(4):244–51.  https://doi.org/10.3109/08037051.2011.561072.PubMedCrossRefGoogle Scholar
  34. 34.
    Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.CrossRefGoogle Scholar
  35. 35.
    Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7):741–51.PubMedCrossRefGoogle Scholar
  36. 36.
    Dell'Omo G, Penno G, Del Prato S, Pedrinelli R. Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. J Cardiovasc Pharmacol Ther. 2005;10(4):265–72.  https://doi.org/10.1177/107424840501000406.PubMedCrossRefGoogle Scholar
  37. 37.
    Leonetti G, Rappelli A, Salvetti A, Scapellato L. Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. Am J Cardiol. 1990;65(17):67H–H71.  https://doi.org/10.1016/0002-9149(90)90347-4.PubMedCrossRefGoogle Scholar
  38. 38.
    Harrower AD, McFarlane G. Antihypertensive therapy in diabetic patients. The use of indapamide. Am J Med. 1988;84(1B):89–91.PubMedGoogle Scholar
  39. 39.
    Osei K, Holland G, Falko JM. Indapamide. Effects on apoprotein, lipoprotein, and glucoregulation in ambulatory diabetic patients. Arch Intern Med. 1986;146(10):1973–7.  https://doi.org/10.1001/archinte.1986.00360220131023.PubMedCrossRefGoogle Scholar
  40. 40.
    Kuo SW, Pei D, Hung YJ, Hsieh AT, Wu LY, Hsieh CH, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens. 2003;16(8):623–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Krum H, Skiba M, Gilbert RE. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Diabet Med. 2003;20(9):708–12.  https://doi.org/10.1046/j.1464-5491.2003.01023.x.PubMedCrossRefGoogle Scholar
  42. 42.
    Vinereanu D, Dulgheru R, Magda S, Dragoi Galrinho R, Florescu M, Cinteza M, et al. The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. Am Heart J. 2014;168(4):446–56.  https://doi.org/10.1016/j.ahj.2014.06.010.PubMedCrossRefGoogle Scholar
  43. 43.
    Emdin CA, Anderson SG, Woodward M, Rahimi K. Usual blood pressure and risk of new-onset diabetes: evidence from 4.1 million adults and a meta-analysis of prospective studies. J Am Coll Cardiol. 2015;66(14):1552–62.  https://doi.org/10.1016/j.jacc.2015.07.059. PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Ong KL, Barter PJ, Waters DD. Cardiovascular drugs that increase the risk of new-onset diabetes. Am Heart J. 2014;167(4):421–8.  https://doi.org/10.1016/j.ahj.2013.12.025.PubMedCrossRefGoogle Scholar
  45. 45.
    Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24(1):3–10.  https://doi.org/10.1097/01.hjh.0000194119.42722.21.PubMedCrossRefGoogle Scholar
  46. 46.
    Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens. 2008;21(5):493–9.  https://doi.org/10.1038/ajh.2008.17.PubMedCrossRefGoogle Scholar
  47. 47.
    Ueda S, Morimoto T, Ando S, Takishita S, Kawano Y, Shimamoto K, et al. A randomised controlled trial for the evaluation of risk for type 2 diabetes in hypertensive patients receiving thiazide diuretics: Diuretics In the Management of Essential hypertension (DIME) study. BMJ Open. 2014;4(7):e004576.  https://doi.org/10.1136/bmjopen-2013-004576.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Lip S, Jeemon P, McCallum L, Dominiczak AF, McInnes GT, Padmanabhan S. Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes. Eur Heart J. 2016;37(12):968–74.  https://doi.org/10.1093/eurheartj/ehv557.PubMedCrossRefGoogle Scholar
  49. 49.
    Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7.  https://doi.org/10.1016/S0140-6736(07)60108-1.PubMedCrossRefGoogle Scholar
  50. 50.
    Nizamuddin M, Elliott WJ. Incident diabetes with antihypertensive drugs: updated network and Bayesian meta-analyses of clinical trial data. J Am Soc Hypertension. 2015;9(Suppl):e24.  https://doi.org/10.1016/j.jash.2015.03.057.CrossRefGoogle Scholar
  51. 51.
    Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med. 1993;118(4):273–8.  https://doi.org/10.7326/0003-4819-118-4-199302150-00005.PubMedCrossRefGoogle Scholar
  52. 52.
    Barzilay JI, Cutler JA, Davis BR. Antihypertensive medications and risk of diabetes mellitus. Curr Opin Nephrol Hypertens. 2007;16(3):256–60.  https://doi.org/10.1097/MNH.0b013e328057dea2.PubMedCrossRefGoogle Scholar
  53. 53.
    Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. The metabolic syndrome in hypertension: European Society of Hypertension Position Statement. J Hypertens. 2008;26(10):1891–900.  https://doi.org/10.1097/HJH.0b013e328302ca38.PubMedCrossRefGoogle Scholar
  54. 54.
    Owen JG, Reisin E. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications. Curr Hypertens Rep. 2015;17(6):558.  https://doi.org/10.1007/s11906-015-0558-9. PubMedCrossRefGoogle Scholar
  55. 55.
    Arroll B, Kenealy T, Elley CR. Should we prescribe diuretics for patients with prediabetes and hypertension? BMJ. 2008;337(aug21 1):a679.  https://doi.org/10.1136/bmj.a679.PubMedCrossRefGoogle Scholar
  56. 56.
    Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4–9.  https://doi.org/10.1161/01.HYP.0000103632.19915.0E.PubMedCrossRefGoogle Scholar
  57. 57.
    Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5:CD003824.  https://doi.org/10.1002/14651858.CD003824.pub2. Google Scholar
  58. 58.
    Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–44.  https://doi.org/10.1001/jama.289.19.2534.PubMedCrossRefGoogle Scholar
  59. 59.
    Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA. 2004;292(1):43–4.  https://doi.org/10.1001/jama.292.1.43-c.PubMedCrossRefGoogle Scholar
  60. 60.
    • Chen P, Chaugai S, Zhao F, Wang DW. Cardioprotective effect of thiazide-like diuretics: a meta-analysis. Am J Hypertens. 2015;28(12):1453–63.  https://doi.org/10.1093/ajh/hpv050. This meta-analysis concludes that thiazide-like diuretics have greater protective effect against cardiovascular events than thiazide-type diuretics, especially on heart failure. PubMedCrossRefGoogle Scholar
  61. 61.
    • Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015;65(5):1033–40.  https://doi.org/10.1161/HYPERTENSIONAHA.114.05122. This systematic review concludes that the best available evidence seems to favor thiazide-like diuretics as the drug of choice when thiazide treatment is considered for hypertension. PubMedCrossRefGoogle Scholar
  62. 62.
    Vongpatanasin W. Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic. Curr Opin Cardiol. 2015;30(4):361–5.  https://doi.org/10.1097/HCO.0000000000000178. PubMedPubMedCentralGoogle Scholar
  63. 63.
    •• de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273–84.  https://doi.org/10.2337/dci17-0026. This Position Statement is intended to update the assessment and treatment of hypertension among patients with diabetes, including advances in care. PubMedCrossRefGoogle Scholar
  64. 64.
    Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438.  https://doi.org/10.1136/bmj.i438.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017;40(Suppl 1):S1–S135.Google Scholar
  66. 66.
    Lievre M, Gueyffier F, Ekbom T, Fagard R, Cutler J, Schron E, et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee. Diabetes Care. 2000;23(Suppl 2):B65–71.PubMedGoogle Scholar
  67. 67.
    Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276(23):1886–92.  https://doi.org/10.1001/jama.1996.03540230036032.PubMedCrossRefGoogle Scholar
  68. 68.
    Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29–35.  https://doi.org/10.1016/j.amjcard.2004.08.059.PubMedCrossRefGoogle Scholar
  69. 69.
    Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40.  https://doi.org/10.1016/S0140-6736(07)61303-8.PubMedCrossRefGoogle Scholar
  70. 70.
    Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, Group CS. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24(12):2091–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Lindholm LH, Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens. 2000;18(11):1671–5.  https://doi.org/10.1097/00004872-200018110-00020.PubMedCrossRefGoogle Scholar
  72. 72.
    Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 2003;41(3):431–6.  https://doi.org/10.1161/01.HYP.0000057420.27692.AD.PubMedCrossRefGoogle Scholar
  73. 73.
    Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010;56(1):77–85.  https://doi.org/10.1016/j.jacc.2010.02.046.PubMedCrossRefGoogle Scholar
  74. 74.
    Puig JG, Marre M, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens. 2007;20(1):90–7.  https://doi.org/10.1016/j.amjhyper.2006.05.018.PubMedCrossRefGoogle Scholar
  75. 75.
    Zhang Y, Agnoletti D, Wang JG, Xu Y, Safar ME. Natriuresis and blood pressure reduction in hypertensive patients with diabetes mellitus: the NESTOR study. J Am Soc Hypertens. 2015;9(1):21–8.  https://doi.org/10.1016/j.jash.2014.10.003.PubMedCrossRefGoogle Scholar
  76. 76.
    Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.  https://doi.org/10.1056/NEJMoa0801369.PubMedCrossRefGoogle Scholar
  77. 77.
    Farsang C. Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO trial. Adv Ther. 2014;31(3):333–44.  https://doi.org/10.1007/s12325-014-0107-y.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56(19):1527–34.  https://doi.org/10.1016/j.jacc.2010.06.034.PubMedCrossRefGoogle Scholar
  79. 79.
    Patterson JH, Adams KF Jr. Investigating the role of thiazide-like diuretics in acute heart failure: potential approach to an unmet need. J Card Fail. 2016;22(7):537–8.  https://doi.org/10.1016/j.cardfail.2016.05.001.PubMedCrossRefGoogle Scholar
  80. 80.
    Trullas JC, Morales-Rull JL, Casado J, Freitas Ramirez A, Manzano L, Formiga F, et al. Rationale and design of the “Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial”: a double-blind, randomized, placebo-controlled study to determine the effect of combined diuretic therapy (loop diuretics with thiazide-type diuretics) among patients with decompensated heart failure. J Card Fail. 2016;22(7):529–36.  https://doi.org/10.1016/j.cardfail.2015.11.003.PubMedCrossRefGoogle Scholar
  81. 81.
    Sica DA. Diuretic use in renal disease. Nat Rev Nephrol. 2011;8(2):100–9.  https://doi.org/10.1038/nrneph.2011.175.PubMedCrossRefGoogle Scholar
  82. 82.
    Izzo JL Jr, Tobe SW. Is there a preferred diuretic class for patients with renal impairment and hypertension? J Am Soc Hypertens. 2016;10(4):282–4.  https://doi.org/10.1016/j.jash.2016.02.008.PubMedCrossRefGoogle Scholar
  83. 83.
    Elliott WJ, Jurca S. Loop diuretics are most appropriate for hypertension treatment in chronic kidney disease. J Am Soc Hypertens. 2016;10(4):285–7.  https://doi.org/10.1016/j.jash.2016.02.007.PubMedCrossRefGoogle Scholar
  84. 84.
    Karadsheh F, Weir MR. Thiazide and thiazide-like diuretics: an opportunity to reduce blood pressure in patients with advanced kidney disease. Curr Hypertens Rep. 2012;14(5):416–20.  https://doi.org/10.1007/s11906-012-0293-4.PubMedCrossRefGoogle Scholar
  85. 85.
    Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2(5):385–95.  https://doi.org/10.1016/S2213-8587(14)70030-0.PubMedCrossRefGoogle Scholar
  86. 86.
    Hoshino T, Ookawara S, Miyazawa H, Ito K, Ueda Y, Kaku Y, et al. Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. Clin Exp Nephrol. 2015;19(2):247–53.  https://doi.org/10.1007/s10157-014-0981-2.PubMedCrossRefGoogle Scholar
  87. 87.
    Donnelly R, Molyneaux LM, Willey KA, Yue DK. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Am J Cardiol. 1996;77(6):26B–30B.  https://doi.org/10.1016/S0002-9149(97)89237-5.PubMedCrossRefGoogle Scholar
  88. 88.
    Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004;22(8):1613–22.  https://doi.org/10.1097/01.hjh.0000133733.32125.09.PubMedCrossRefGoogle Scholar
  89. 89.
    Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes preterax in albuminuria regression: PREMIER. Hypertension. 2003;41(5):1063–71.  https://doi.org/10.1161/01.hyp.0000064943.51878.58.PubMedCrossRefGoogle Scholar
  90. 90.
    Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2010;31(23):2888–96.  https://doi.org/10.1093/eurheartj/ehq139.PubMedCrossRefGoogle Scholar
  91. 91.
    Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59.  https://doi.org/10.1007/s40265-014-0337-y.PubMedCrossRefGoogle Scholar
  92. 92.
    Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.  https://doi.org/10.1056/NEJMoa1504720.PubMedCrossRefGoogle Scholar
  93. 93.
    McMurray J. EMPA-REG—the “diuretic hypothesis”. J Diabetes Complicat. 2016;30(1):3–4.  https://doi.org/10.1016/j.jdiacomp.2015.10.012.PubMedCrossRefGoogle Scholar
  94. 94.
    Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in EMPA-REG OUTCOME: comparison with classic diuretics. Diabetes Metab. 2016;42(4):224–33.  https://doi.org/10.1016/j.diabet.2016.05.006.PubMedCrossRefGoogle Scholar
  95. 95.
    Scheen AJ, Delanaye P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab. 2017;43(2):99–109.  https://doi.org/10.1016/j.diabet.2016.12.010.PubMedCrossRefGoogle Scholar
  96. 96.
    Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther. 2014;36(5):698–710.  https://doi.org/10.1016/j.clinthera.2014.02.022.PubMedCrossRefGoogle Scholar
  97. 97.
    Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obesity Metab. 2013;15(9):853–62.  https://doi.org/10.1111/dom.12127.CrossRefGoogle Scholar
  98. 98.
    Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obesity Metab. 2015;17(8):805–8.  https://doi.org/10.1111/dom.12486.CrossRefGoogle Scholar
  99. 99.
    Heise T, Mattheus M, Woerle HJ, Broedl UC, Macha S. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Clin Ther. 2015;37(4):793–803.  https://doi.org/10.1016/j.clinthera.2014.12.018.PubMedCrossRefGoogle Scholar
  100. 100.
    Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. Clin Ther. 2016;38(10):2248–64 e5.  https://doi.org/10.1016/j.clinthera.2016.08.008.PubMedCrossRefGoogle Scholar
  101. 101.
    Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.  https://doi.org/10.1056/NEJMoa1611925.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU LiègeUniversity of LiègeLiegeBelgium
  2. 2.Clinical Pharmacology Unit, CHU Liège, Center for Interdisciplinary Research on Medicines (CIRM)University of LiègeLiègeBelgium

Personalised recommendations